Kristeleit, Rebecca http://orcid.org/0000-0003-3825-1326
Plummer, Ruth
Jones, Robert
Carter, Louise
Blagden, Sarah http://orcid.org/0000-0001-8783-3491
Sarker, Debashis http://orcid.org/0000-0003-4814-8429
Arkenau, Tobias
Evans, Thomas R. Jeffry
Danson, Sarah
Symeonides, Stefan N. http://orcid.org/0000-0002-9892-9314
Veal, Gareth J.
Klencke, Barbara J.
Kowalski, Mark M.
Banerji, Udai http://orcid.org/0000-0003-1503-3123
Funding for this research was provided by:
Cancer Research UK
DH | National Institute for Health Research (RP-2016-07-028)
Sierra Oncology Experimental Cancer Medical Centres (UK) National Institute of Health and Care Research Biomedical Research Centres
Article History
Received: 15 November 2022
Revised: 3 April 2023
Accepted: 13 April 2023
First Online: 29 April 2023
Competing interests
: SRA737 was discovered in collaboration with The Institute of Cancer Research, London, UK (ICR). UB is an employee of ICR but does not receive royalties for discovery of SRA737. UB has spoken at Sierra Oncology and AVACTA advisory boards (non-remunerated) and has received honoraria from Pegasys, Boehringer Ingelheim, Idea Pharma, Novartis, and Karus Therapeutics unrelated to the presented work. He has received research funding from Avacta, Verastem Oncology, Chugai, Carrick Therapeutics, BTG, and Onyx all unrelated to this work. Evans is Clinical Subjects Editor, British Journal of Cancer. SB has received research funding from Nucana PLC, Astex, Incyte, Tesaro, Redx, MSD, Roche, UCB and consulting fees from Ellipses and Theolytics, unrelated to this work.
: Research ethics committees approved the study protocol before initiation of patient enrolment, and all patients provided written informed consent prior to study enrolment in accordance with the Declaration of Helsinki, the International Conference on Harmonisation Guidelines for Good Clinical Practice, and applicable local regulations. The study was approved in the United Kingdom by the Research Ethics Committees London Centre.
: Not applicable.